OS Therapies Incorporated - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
OSTX NYSE American 2836 ostherapies.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for OS Therapies Incorporated

OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial - Nov 5th, 2026 6:00 am
OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million - Oct 19th, 2026 6:30 am
Rubenstein Public Relations Named Agency of Record for OS Therapies - Oct 8th, 2026 7:22 am
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma - Oct 7th, 2026 6:30 am
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial - Oct 6th, 2026 6:30 am
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer - Oct 1st, 2026 6:30 am
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) - Sep 24th, 2026 6:22 am
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis - Sep 21st, 2026 4:30 am
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program - Sep 17th, 2026 4:00 am
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing - Sep 15th, 2026 5:46 am
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial - Sep 8th, 2026 4:00 am
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance - Sep 2nd, 2026 5:20 am
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates - Aug 17th, 2026 5:40 am
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma - Aug 13th, 2026 6:45 am
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program - Jul 8th, 2026 7:00 am
OS Therapies Third Quarter 2026 Corporate Outlook - Jul 6th, 2026 7:00 am
OS Therapies Appoints Dr. Craig Eagle to Board of Directors - Jul 2nd, 2026 5:30 am
OS Therapies Provides U.S. Regulatory Update - Jun 30th, 2026 5:40 am
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma - Jun 26th, 2026 5:40 am
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma - Jun 8th, 2026 4:00 am